MedTrace Logo

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

DRUG

VX-993

Tablets for oral administration.

DRUG

Pregabalin

Capsules for oral administration.

DRUG

Placebo (matched to pregabalin)

Placebo matched to pregabalin for oral administration.

DRUG

Placebo (matched to VX-993)

Placebo matched to VX-993 for oral administration.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-18
Primary Completion
2026-04-30
Completion
2026-05-30
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06619860 on ClinicalTrials.gov